問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Otolaryngology

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

Division of Colorectal Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

National Taiwan University Hospital

更新時間：2023-09-19

邱泰然Chiu, Tai-Jan
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 2 個月

  • kuerten@cgmh.org.tw

Recruiting Trial

116Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱泰然

List

220Cases

2022-04-01 - 2028-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-12-01 - 2026-11-30

Phase III

Active
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    靜脈點滴注射劑

Participate Sites
5Sites

Recruiting5Sites

2024-11-01 - 2028-09-30

Phase I

Active
An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors

  • Condition/Disease

    Advanced Tumors

  • Test Drug

    tablets

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2022-08-31 - 2031-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2018-07-03 - 2020-08-31

Phase III

Completed
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    BGB-A317

Participate Sites
8Sites

Terminated7Sites

林振源
China Medical University Hospital-Taipei

未分科

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-06-01 - 2024-09-30

Phase III

Completed
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy and safety of tislelizumab (BGB-A317) in combination with chemotherapy as first-line treatment in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma

  • Condition/Disease

    unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma

  • Test Drug

    BGB-A317

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

林振源
China Medical University Hospital

Division of Hematology & Oncology

2020-07-22 - 2025-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-09-01 - 2030-06-30

Phase II

Active
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection Condensed Powder

Participate Sites
7Sites

Recruiting7Sites

2025-09-10 - 2028-06-13

Phase I

Not yet recruiting
A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  • Condition/Disease

    Advanced Clear Cell Renal Cell Carcinoma

  • Test Drug

    N/A N/A

Participate Sites
4Sites

Recruiting4Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

1 9 10 11 12 13 22
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB